OverTheCounterToday

This Week In OTCs And Nutritionals

This week's issue of "The Tan Sheet" tracks a spike in mergers and acquisitions as Schiff Nutrition International buys Airborne, Genomma Lab pushes forward on its unsolicited bid to take over Prestige Brands Holdings and Somaxon seeks a partner to help switch Silenor.

We also look at the latest in an advocacy group’s litigation to expand OTC access to emergency contraceptives and at studies needed to make an anthrax MedKit potentially available for home use. 

Click here for a full table of contents for the April 9 issue. 

"The Tan Sheet" is your source for the most comprehensive and in-depth coverage of the OTC drug and nutritional industries. Start your free trial subscription here -- no credit card required.

Also, follow "The Tan Sheet" on Twitter and Facebook.

-- Elizabeth Crawford (e.crawford@elsevier.com)

"The Tan Sheet": New Paradigm Needs Clear Switch Criteria, Standard Dispensing Rules

 

"The Tan Sheet" is your go-to source for coverage and analysis of FDA's proposed "new paradigm" for approving nonprescription pharmaceuticals under conditions of safe use. See below for a sample of our extensive coverage of the agency's recent public hearing.

Get the most in-depth reporting on the OTC pharma and nutritional industries in "The Tan Sheet." Your free trial subscription begins here -- no credit card required.

Your company or organization may already provide access to "The Tan Sheet." To find out if you should have access, email custcare@elsevier.com.

Also, follow "The Tan Sheet" on Twitter and Facebook.

This Week In OTCs And Nutritionals: FDA Hears Concerns About Allowing Novel Switches

Health care industry experts' comments to FDA show that clearing alternative routes to nonprescription status will encounter bumps and generate concerns, as you’ll read in the April 2 issue of “The Tan Sheet.”

At a public hearing on ideas about making more drugs available nonprescription but “under conditions of safe use,” stakeholders questioned whether some prescription "antidotes" should be switched to restricted nonprescription status, and noted that  drug firms likely will not invest in novel switches without market exclusivity and a requirement to make generics also subject to consumer access restrictions. 

In this issue we also report on the Health Choices Coalition urging Congress to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.

For much more, and "The Tan Sheet's" April 2 table of contents, click here.

"The Tan Sheet" is your source for the most comprehensive and in-depth coverage of the OTC drug and nutritional industries. Start your free trial subscription here -- no credit card required.Your company or organization may already provide access to "The Tan Sheet." To find out if you should have access, email custcare@elsevier.com.

Also, follow "The Tan Sheet" on Twitter and Facebook.

-- Malcolm Spicer (m.spicer@elsevier.com)